Results 11 to 20 of about 25,818 (186)

Clinical Progression Modes of Crizotinib Failure and Subsequent Management of Advanced Non‐Small Cell Lung Cancer With ROS1 Rearrangement [PDF]

Cancer Med
Survival outcomes in gradual/local progression group were superior to dramatic progression group; survival period of dramatic progression group who received chemotherapy was longer than that of other therapies. ROS1 kinase domain mutations were detected predominantly in dramatic progression group, whereas activation of bypass and downstream pathways ...
Tan Q, Chen Y, Gao Y, Liu K, Mao Z, Zheng M, Su J, Yang J, Gao Q, Chen H, Yang J.   +10 more
europepmc   +2 more sources

Influence of Chirality of Crizotinib on Its MTH1 Protein Inhibitory Activity: Insight from Molecular Dynamics Simulations and Binding Free Energy Calculations.

PLoS ONE, 2015
As a promising target for the treatment of lung cancer, the MutT Homolog 1 (MTH1) protein can be inhibited by crizotinib. A recent work shows that the inhibitory potency of (S)-crizotinib against MTH1 is about 20 times over that of (R)-crizotinib.
Yuzhen Niu, Dabo Pan, Danfeng Shi, Qifeng Bai, Huanxiang Liu, Xiaojun Yao   +5 more
doaj   +1 more source

Characteristics of central nervous system progression in non‐small cell lung cancer treated with crizotinib or alectinib

Cancer Reports, 2021
Background Most patients treated with anaplastic lymphoma kinase (ALK)‐tyrosine kinase inhibitors for ALK‐positive non‐small cell lung cancer (NSCLC) develop resistance, leading to metastasis, with progression to the central nervous system (CNS) being a ...
Hiroaki Sakamoto, Noriko Yanagitani, Ryo Manabe, Ryosuke Tsugitomi, Shinsuke Ogusu, Takehiro Tozuka, Hiroshi Yoshida, Yoshiaki Amino, Ryo Ariyasu, Ken Uchibori, Satoru Kitazono, Sadatomo Tasaka, Makoto Nishio   +12 more
doaj   +1 more source

A Case of Lung Adenocarcinoma With Concurrent EGFR Mutation and ALK Fusion Combined With Literature Review. [PDF]

Clin Case Rep
ABSTRACT This case underscores the critical importance of retesting for resistant mechanisms, such as EML4‐ALK fusion, in patients with EGFR‐mutant lung adenocarcinoma who experience rapid progression on EGFR‐tyrosine kinase inhibitor (TKI) therapy. Early identification of such co‐alterations and an immediate switch to alectinib can lead to rapid and ...
Chen Y, Qi F, Zeng Y, Tan J, Hu M, Zhang H, Zhang T.   +6 more
europepmc   +2 more sources

ALK Positive Lung Cancer: Clinical Profile, Practice and Outcomes in a Developing Country. [PDF]

PLoS ONE, 2016
OBJECTIVES:To evaluate the performance and treatment profile of advanced EML4-ALK positive Non-small cell lung cancer (NSCLC) patients in a developing country with potentially restricted access to Crizotinib.
Vanita Noronha, Anant Ramaswamy, Vijay M Patil, Amit Joshi, Anuradha Chougule, Subhadha Kane, Rajiv Kumar, Arvind Sahu, Vipul Doshi, Lingaraj Nayak, Abhishek Mahajan, Amit Janu, Kumar Prabhash   +12 more
doaj   +1 more source

Crizotinib-induced antitumour activity in human alveolar rhabdomyosarcoma cells is not solely dependent on ALK and MET inhibition [PDF]

, 2015
BACKGROUND: Rhabdomyosarcoma (RMS) is the most commonly diagnosed malignant soft tissue tumour in children and adolescents. Aberrant expression of Anaplastic Lymphoma Kinase (ALK) and MET gene has been implicated in the malignant progression of RMS ...
CAMERO, SIMONA, CECCARELLI, SIMONA, CLERICO, Anna, DOMINICI, Carlo, Losty, Paul D, Mannarino, Olga, Mcdowell, Heather P, MEGIORNI, Francesca, PAIANO, MILENA, Pizer, Barry, PIZZUTI, Antonio, Shukla, Rajeev   +11 more
core   +1 more source

Hexokinases II‐mediated glycolysis governs susceptibility to crizotinib in ALK‐positive non‐small cell lung cancer

Thoracic Cancer, 2021
Background Activation of ALK leads to a high level of aerobic glycolysis related to crizotinib insensitivity in anaplastic lymphoma kinase‐positive non‐small cell lung cancer (ALK+ NSCLC).
Caiyu Lin, Hengyi Chen, Rui Han, Li Li, Conghua Lu, Shuai Hao, Yubo Wang, Yong He   +7 more
doaj   +1 more source

Early and late effects of pharmacological ALK inhibition on the neuroblastoma transcriptome [PDF]

, 2017
Background: Neuroblastoma is an aggressive childhood malignancy of the sympathetic nervous system. Despite multi-modal therapy, survival of high-risk patients remains disappointingly low, underscoring the need for novel treatment strategies.
Cannoodt, Robrecht, Claeys, Shana, De Preter, Katleen, Denecker, Geertrui, Durinck, Kaat, Kumps, Candy, Speleman, Franki   +6 more
core   +3 more sources

Symptomatic CNS Radiation Necrosis Requiring Neurosurgical Resection During Treatment with Lorlatinib in ALK-Rearranged NSCLC: A Report of Two Cases. [PDF]

, 2020
Central nervous system (CNS) metastasis carries a significant morbidity and mortality in anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC).
Al-Holou, Wajd, Armas, Octavio, Kubota, Takafumi, Nagasaka, Misako, Ou, Sai-Hong Ignatius, Raval, Kunil, Robinette, Natasha, Zhu, Viola W   +7 more
core   +1 more source

Crizotinib Shows Antibacterial Activity against Gram-Positive Bacteria by Reducing ATP Production and Targeting the CTP Synthase PyrG

Microbiology Spectrum, 2022
Infections caused by drug-resistant bacteria are a serious threat to public health worldwide, and the discovery of novel antibacterial compounds is urgently needed.
Yun-Dan Zheng, Tairan Zhong, Haiming Wu, Nan Li, Zuye Fang, Linlin Cao, Xing-Feng Yin, Qing-Yu He, Ruiguang Ge, Xuesong Sun   +9 more
doaj   +1 more source